Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for KalVista Pharmaceuticals (KALV) over the last 10 years, with Q2 2025 value amounting to $8.1 million.

  • KalVista Pharmaceuticals' Change in Accured Expenses rose 43326.49% to $8.1 million in Q2 2025 from the same period last year, while for Apr 2025 it was $8.9 million, marking a year-over-year increase of 17862.26%. This contributed to the annual value of $14.4 million for FY2025, which is 34964.16% up from last year.
  • KalVista Pharmaceuticals' Change in Accured Expenses amounted to $8.1 million in Q2 2025, which was up 43326.49% from $5.0 million recorded in Q4 2024.
  • KalVista Pharmaceuticals' 5-year Change in Accured Expenses high stood at $8.1 million for Q2 2025, and its period low was -$2.4 million during Q2 2024.
  • Its 3-year average for Change in Accured Expenses is $2.1 million, with a median of $2.9 million in 2024.
  • In the last 5 years, KalVista Pharmaceuticals' Change in Accured Expenses crashed by 4322.58% in 2024 and then skyrocketed by 43326.49% in 2025.
  • Quarter analysis of 3 years shows KalVista Pharmaceuticals' Change in Accured Expenses stood at $4.0 million in 2023, then rose by 25.49% to $5.0 million in 2024, then skyrocketed by 61.11% to $8.1 million in 2025.
  • Its Change in Accured Expenses was $8.1 million in Q2 2025, compared to $5.0 million in Q4 2024 and -$1.8 million in Q3 2024.